Fujifilm Diosynth Outlines $850-M Mfg Expansion Plan
Fujifilm Corporation has announced it will invest a 90 billion Yen ($850 million) to expand Fujifilm Diosynth Biotechnologies, its biologics CDMO and subsidiary.
The 90-billion Yen ($850-million) investment will double Fujifilm Diosynth Biotechnologies’ cell-culture production for recombinant vaccines in the US. In the UK, gene-therapy production will be increased ten-fold, cell-culture capacity will be tripled and microbial fermentation output at the existing 5,000-L scale facility will be doubled. The UK cell-culture expansion will also include capacity for continuous manufacturing. Process and analytical development capacity will also be added.
The expansions are scheduled to begin operating by late 2023. Fujifilm says that further details on the capabilities of the new and expanded facilities will be disclosed upon conclusion of initial engineering studies that are currently ongoing.
